Eli Lilly and Company (NYSE:LLY) Shares Bought by Arete Wealth Advisors LLC

Arete Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 37.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,454 shares of the company's stock after buying an additional 2,016 shares during the quarter. Arete Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $5,750,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Motley Fool Asset Management LLC grew its holdings in Eli Lilly and Company by 0.9% during the 4th quarter. Motley Fool Asset Management LLC now owns 39,375 shares of the company's stock worth $30,398,000 after acquiring an additional 370 shares in the last quarter. World Investment Advisors raised its stake in Eli Lilly and Company by 14.9% in the fourth quarter. World Investment Advisors now owns 16,574 shares of the company's stock worth $12,795,000 after buying an additional 2,145 shares in the last quarter. Disciplined Investors L.L.C. purchased a new stake in Eli Lilly and Company during the fourth quarter worth $207,000. OneAscent Financial Services LLC boosted its position in Eli Lilly and Company by 179.6% during the 4th quarter. OneAscent Financial Services LLC now owns 4,798 shares of the company's stock valued at $3,704,000 after acquiring an additional 3,082 shares in the last quarter. Finally, Private Portfolio Partners LLC increased its holdings in shares of Eli Lilly and Company by 16.8% in the 4th quarter. Private Portfolio Partners LLC now owns 3,189 shares of the company's stock valued at $2,462,000 after acquiring an additional 459 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Remove Ads

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $51.53 during trading hours on Friday, reaching $737.56. The stock had a trading volume of 5,289,016 shares, compared to its average volume of 3,326,912. The stock's 50 day moving average is $848.36 and its 200 day moving average is $831.93. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The firm has a market capitalization of $699.33 billion, a PE ratio of 62.99, a PEG ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has approved a share repurchase plan on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to buy up to 2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Bank of America restated a "buy" rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Citigroup reduced their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Finally, Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,009.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.